Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension

European Heart Journal

Volumn 26, Issue 18, 2005, Pages 1895-1902

  Opitz, Christian F ^a   Wensel, Roland ^b   Winkler, Jörg ^c   Halank, Michael ^d   Bruch, Leonhard ^e   Kleber, Franz Xaver ^e   Höffken, Gert ^d   Anker, Stefan D ^f   Negassa, Abdissa ^g   Felix, Stephan B ^h   Hetzer, Roland ⁱ   Ewert, Ralf ^h  

^a DRK KLINIKEN BERLIN WESTEND   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Unfallkrankenhaus Berlin ^*  (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF GREIFSWALD   (Germany)

ⁱ DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Chronic therapy; Inhaled iloprost; Pulmonary arterial hypertension

Indexed keywords

BERAPROST; BOSENTAN; ILOPROST; PROSTANOID;

ADULT; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; EXERCISE; FEMALE; FOLLOW UP; HEART ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SURVIVAL; TRANSPLANTATION;

ADMINISTRATION, INHALATION; ADULT; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VASODILATOR AGENTS;

EID: 21544449424     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi283     Document Type: Article

References (31)

1. Sitbon O, Humbert M, Nunes H et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
2. McLaughlin VV, Gaine SP, Barst RJ et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003;41:293-299.
3. Wensel R, Opitz CF, Anker SD et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002;106:319-324.
4. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
5. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502.
6. Simonneau G, Barst RJ, Galie N et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
7. Olschewski H, Simonneau G, Galie N et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
8. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
9. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000;132:435-443.
10. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-1870.
11. Wensel R, Opitz CF, Ewert R et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000;101:2388-2392.
12. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-223.
13. Rich S. World Symposium on Primary Pulmonary Hypertension 1998: Executive Summary. http://www.who.int/ncd/cvd/pph.html
14. Olschewski H, Walmrath D, Schermuly R et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-824.
15. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003;124:1294-1304.
16. Kleber FX, Vietzke G, Wernecke KD et al. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation 2000;101:2803-2809.
17. Higenbottam T, Butt AY, McMahon A et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80:151-155.
18. British Cardiac Society Guidelines and Medical Practice Committee, and approved by the British Thoracic Society and the British Society of Rheumatology. Recommendations on the management of pulmonary hypertension in clinical practice. Heart 2001;86(Suppl. 1):I1-13.
19. Hoeper MM, Spiekerkoetter E, Westerkamp V et al. Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. Eur Respir J 2002;20:339-343.
20. Maurer JR, Frost AE, Estenne M et al. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998;66:951-956.
21. Schoenfeld D. Chi-squared goodness of fit tests for the proportional hazards regression model. Biometrika 1980;67:145-153.
22. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
23. Olschewski H, Nikkho S, Behr J et al. Long-term survival in patients with pulmonary hypertension inhaling iloprost (AIR-2 study). (Abstract). Vienna: European Society of Cardiology Congress; 2003.
24. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-1502.
25. Barst RJ, McGoon M, McLaughlin V et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-2125.
26. Sitbon O, Badesch DB, Channick RN et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-254.
27. McLaughlin V, Sitbon O, Rubin LJ et al. The effect of first-line bosentan on survival of patients with primary pulmonary hypertension. (B087 Abstract). ATS Conference Seattle; 2003.
28. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000;132:435-443.
29. Gessler T, Schmehl T, Hoeper MM et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001;17:14-19.
30. Opitz CF, Wensel R, Bettmann M et al. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24:356-365.
31. Hoeper MM, Taha N, Bekjarova A et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003;22:330-334.